Distinguished in Sertoli-Leydig Cell Tumor

Dr. Gerardo Colon-Otero

Hematology Oncology | Hematology | Oncology
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
46 Years of Experience
Distinguished in Sertoli-Leydig Cell Tumor
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gerardo Colon-Otero is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Colon-Otero has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Splenectomy. Dr. Colon-Otero is currently accepting new patients.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Puerto Rico School Of Medicine, 1979
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mayo Clinic
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

MAYO CLINIC JACKSONVILLE
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
Enrollment Status: Recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
Differences in Immunological Effects of Vitamin D Replacement Among Black/African American (AA) Prostate Cancer Patients With Localized Versus Metastatic Disease
Differences in Immunological Effects of Vitamin D Replacement Among Black/African American (AA) Prostate Cancer Patients With Localized Versus Metastatic Disease
Enrollment Status: Recruiting
Publish Date: September 12, 2025
Intervention Type: Other, Dietary supplement, Procedure
Study Phase: Early Phase 1
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: August 26, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Gemcitabine Hydrochloride, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Acceptance and Completion Rate of Free HPV Vaccination Among Underserved Adult Patients (Age 18-45)
Acceptance and Completion Rate of Free HPV Vaccination Among Underserved Adult Patients (Age 18-45)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Other
Study Phase: Phase 4
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Enrollment Status: Completed
Publish Date: December 05, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.
A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.
Enrollment Status: Completed
Publish Date: October 26, 2021
Intervention Type: Drug, Other
Study Drugs: Letrozole, Ribociclib
Study Phase: Phase 2
View 9 Less Clinical Trials

55 Total Publications

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.
Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 10, 2024
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Carlos M. Castillo
Hematology Oncology | Oncology | Hematology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Carlos M. Castillo
Hematology Oncology | Oncology | Hematology

Shands Jacksonville Medical Center Inc

1699 S 14th St, Suite 1, 
Fernandina Beach, FL 
 (26.6 miles away)
904-427-1370
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Carlos Castillo is a Hematologist Oncology specialist and an Oncologist in Fernandina Beach, Florida. Dr. Castillo is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, and Sertoli-Leydig Cell Tumor. Dr. Castillo is currently accepting new patients.

Distinguished in Sertoli-Leydig Cell Tumor
Dr. Matthew W. Robertson-Iii
Gynecologic Oncology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Matthew W. Robertson-Iii
Gynecologic Oncology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Robertson-Iii is a Gynecologic Oncologist and an Oncologist in Jacksonville, Florida. Dr. Robertson-Iii is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, Hysterectomy, and Hernia Surgery. Dr. Robertson-Iii is currently accepting new patients.

Advanced in Sertoli-Leydig Cell Tumor
Dr. Daniel A. Kobrinski
Hematology Oncology | Oncology | Hematology
Advanced in Sertoli-Leydig Cell Tumor
Dr. Daniel A. Kobrinski
Hematology Oncology | Oncology | Hematology

Cancer Specialists LLC

700 3rd St, Suite 302, 
Neptune Beach, FL 
 (4.6 miles away)
904-997-3800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Kobrinski is a Hematologist Oncology specialist and an Oncologist in Neptune Beach, Florida. Dr. Kobrinski is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Breast Cancer. Dr. Kobrinski is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Colon-Otero's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 80 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile